Abbott Laboratories stock gains 0.36 percent as revenue reaches USD 12.6 billion

Published on 09/22/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock rose to USD 102.98 on September 21, 2026, while second-quarter revenue reached USD 12.6 billion. EPS came in at USD 1.31.

Modernes Diagnostik-Labor Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories stock (ISIN US0028241000) closed at USD 102.98 on the NYSE on September 21, 2026, up 0.36 percent from USD 102.61. The move followed a second-quarter revenue figure of USD 12.6 billion and adjusted earnings per share of USD 1.31, according to figures reported for the quarter ended June 30, 2026.

Revenue reaches USD 12.6 billion

Abbott reported approximately USD 12.6 billion in revenue for the quarter ended June 30, 2026, compared with about USD 10.6 billion in the quarter ended September 30, 2024. That increase of roughly USD 2.0 billion across the comparison period gives the latest sales figure more weight than the modest daily stock move.

According to Money365 on September 21, 2026, Abbott's last reported quarter was Q2 2026, with EPS of USD 1.31 versus an estimate of USD 1.29. The USD 0.02 difference represents a quantified comparison with expectations, while the reported operating margin for the June 2026 quarter was about 14 percent.

Stock remains below yearly high

The latest quoted price of USD 102.98 leaves Abbott stock below the 52-week high of USD 137.49 and above the 52-week low of USD 81.97, both shown in the September 21, 2026 market snapshot. The same data set recorded a session range of USD 101.84 to USD 103.20 and volume equal to 3.52 times the 20-day average.

For investors, the contrast is clear: revenue expanded from USD 10.6 billion to USD 12.6 billion in the cited comparison, yet the share price remains closer to the lower half of its 52-week range than to the high. That combination places greater emphasis on the next earnings update and on whether operating profitability stays near the 14 percent level reported for Q2 2026.

Settlement adds a quantified risk

According to TradingView on September 21, 2026, Abbott agreed to a USD 385 million civil settlement related to alleged contaminated infant formula from plants in Sturgis and Casa Grande. The report also said Abbott confirmed a quarterly dividend of USD 0.63 payable on November 16, 2026, creating a material legal counter-factor alongside the latest operating figures.

NYSE price stays at USD 102.98

Abbott Laboratories stock closed at USD 102.98 on the NYSE on September 21, 2026, with a daily gain of 0.36 percent from the prior close of USD 102.61. The price, session range, volume and 52-week range are dated to that completed trading session.